Raquel
Flores Hernández
Instituto de Neurociencias de Castilla y León
Salamanca, EspañaPublicacións en colaboración con investigadores/as de Instituto de Neurociencias de Castilla y León (5)
2024
-
A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma
Translational Research, Vol. 272, pp. 95-110
-
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models
Neuro-Oncology, Vol. 26, Núm. 7, pp. 1230-1246
2020
-
Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo
Neuro-Oncology, Vol. 22, Núm. 4, pp. 493-504
-
Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283
EBioMedicine, Vol. 62